Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bimatoprost 0.01% vs LUMIGAN in Glaucoma and Ocular Hypertension
NCT04890106Phase 3Completed
- Sponsor
- Mankind Pharma
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of bimatoprost in Open-angle glaucoma (OAG), ocular hypertension, sponsored by Mankind Pharma. Started Oct 2021; status: completed.
02
Drugs
bimatoprost
03
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT04890106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890106.